GSK plc with ticker (LON:GSK) now has a potential upside of 21.3% according to Deutsche.
GSK.L
Deutsche set a target price of 1,950 GBX for the company, which when compared to the GSK plc share price of 1,608 GBX at opening today (21/06/2024) indicates a potential upside of 21.3%. Trading has ranged between 1,303 (52 week low) and 1,824 (52 week high) with an average of 7,981,977 shares exchanging hands daily. The market capitalisation at the time of writing is £66,070,726,160.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
GSK plc 21.3% potential upside indicated by Deutsche
- Written by: Charlotte Edwards
Latest Company News
GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.
GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis.
GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over.
GSK will receive a $370 million upfront payment, plus 1% royalties on US sales of certain mRNA vaccines by BioNTech and Pfizer, following a settlement linked to CureVac’s recent agreement with BioNTech.
